Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 9/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.45 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.43 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.43 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.43 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2663144 | 0.88 | ACKR3 (0.45) | ACKR3FFAR1ACHENR3C1NPC1 | |
| SCHEMBL2663137 | 0.84 | ACHE (0.54) | FFAR1PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL2663028 | 0.77 | NPC1 (0.49) | ACKR3NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL4096606 | 0.74 | GCGR (0.45) | ACKR3 | |
| SCHEMBL2661984 | 0.72 | AKT3 (0.42) | ACKR3 | |
| SCHEMBL4087544 | 0.71 | KDM4E (0.44) | RAB9ASMN1; SMN2 | |
| SCHEMBL2663063 | 0.69 | KMT2A (0.51) | NPC1USP2RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL31687502 | 0.69 | ACKR3 (1.00) | ACKR3 | |
| SCHEMBL2203343 | 0.68 | HDAC1 (0.80) | PLAAT3PLAAT5PLAAT2PLAAT4NPC1 | |
| SCHEMBL2169060 | 0.68 | PPARD (0.55) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| CN-1356977-A | Glucagon antagonists/inverse agonists | NOVO NORDISK AS (DK) | 2002-07-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | ACKR3 642/4885FFAR1 72/4885PLAAT3 1932/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | ACKR3 642/4885FFAR1 72/4885PLAAT3 1932/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | ACKR3 642/4885FFAR1 72/4885PLAAT3 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.